- Home
- FUN vs CRSP Comparison
FUN vs CRSP Comparison
Compare FUN & CRSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FUN
- CRSP
- Stock Information
- Founded
- FUN 1983
- CRSP 2013
- Country
- FUN United States
- CRSP Switzerland
- Employees
- FUN N/A
- CRSP N/A
- Industry
- FUN Services-Misc. Amusement & Recreation
- CRSP Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- FUN Consumer Discretionary
- CRSP Health Care
- Exchange
- FUN Nasdaq
- CRSP Nasdaq
- Market Cap
- FUN 3.8B
- CRSP 3.4B
- IPO Year
- FUN 1987
- CRSP 2016
- Fundamental
- Price
- FUN $35.43
- CRSP $36.99
- Analyst Decision
- FUN Strong Buy
- CRSP Buy
- Analyst Count
- FUN 14
- CRSP 19
- Target Price
- FUN $54.57
- CRSP $74.35
- AVG Volume (30 Days)
- FUN 1.7M
- CRSP 1.6M
- Earning Date
- FUN 05-08-2025
- CRSP 05-07-2025
- Dividend Yield
- FUN 0.85%
- CRSP N/A
- EPS Growth
- FUN N/A
- CRSP N/A
- EPS
- FUN N/A
- CRSP N/A
- Revenue
- FUN $2,708,926,000.00
- CRSP $37,314,000.00
- Revenue This Year
- FUN $27.65
- CRSP $49.76
- Revenue Next Year
- FUN $4.74
- CRSP $257.28
- P/E Ratio
- FUN N/A
- CRSP N/A
- Revenue Growth
- FUN 50.61
- CRSP N/A
- 52 Week Low
- FUN $33.83
- CRSP $36.52
- 52 Week High
- FUN $58.70
- CRSP $68.39
- Technical
- Relative Strength Index (RSI)
- FUN 37.18
- CRSP 34.31
- Support Level
- FUN $36.35
- CRSP $40.41
- Resistance Level
- FUN $39.08
- CRSP $42.72
- Average True Range (ATR)
- FUN 1.53
- CRSP 1.73
- MACD
- FUN 0.14
- CRSP -0.55
- Stochastic Oscillator
- FUN 29.74
- CRSP 0.80
About FUN Cedar Fair L.P.
Six Flags Entertainment Corp is North America's regional amusement resort operator with approximately 27 amusement parks, around 15 separately gated water parks, and nine resort properties across the U.S., Canada, and Mexico. It provides coasters, themed rides, thrilling water parks, resorts, and a portfolio of beloved intellectual properties such as Looney Tunes, DC Comics, and PEANUTS.
About CRSP CRISPR Therapeutics AG
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.